Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Dodgy Ticker who wrote (9601)	11/29/2003 1:20:59 PM
From: Biomaven	Read Replies (2) of 52153

Bob, It's important to remember that for any company that has options, there is already the potential of an unlimited short position. So certainly in the bigger companies at least allowing legal naked shorting would have little or no effect in my view. The microcaps are somewhat different. The issue there is the ever-present potential for price manipulation, both up by pumpers and down by shady shorters. In my view restrictions on shorting recent IPO's was one of the causes of the 2000/2001 IPO bubble. If the shorts hadn't been creamed in the early stages of the biotech bubble I believe we wouldn't have risen so high or fallen so hard. So I think shorts in general do the market a service. Unfortunately there are unscrupulous shorts that spread unfounded rumors that can do any small biotech serious harm. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next